LC1343

LC1343 (72 h) potently inhibits the growth of A2780 ovarian, A2780/CP cisplatin-resistant ovarian, and HCT116 colorectal cancer cells with IC₅₀ values of 11 μM, 18.8 μM, and 24.6 μM, respectively^[1].
LC1343 (7-11 μM; 72 h with electroporation) has its cytotoxicity synergistically enhanced by electroporation in A2780 ovarian cancer cells, increasing growth inhibition from 29.5% to 62.5% at 7 μM and from 49.1% to 71.7% at 11 μM, with SQ values of 1.83 and 1.33, respectively^[1].
LC1343 (5-16 μM; 72 h with electroporation) has its cytotoxicity enhanced by electroporation in A2780/CP cisplatin-resistant ovarian cancer cells, increasing growth inhibition from 24.9% to 61.7% at 5 μM and from 47.1% to 66.0% at 16 μM^[1].
LC1343 (10-30 μM; 72 h with electroporation) has its cytotoxicity strongly synergistically enhanced by electroporation in HCT116 colorectal cancer cells, increasing growth inhibition from 6.1% to 35.5% at 10 μM and from 44.7% to 64.4% at 30 μM^[1].
LC1343 inhibits growth of multiple cancer cell lines, including 5-FU (HY-90006)-resistant LPc167 pancreatic adenocarcinoma cells with high hTS levels, and exhibits consistent activity against PDAC-2 and PDAC-5 pancreatic adenocarcinoma cells^[2].
LC1343 induces apoptotic cell death in Cisplatin (HY-17394)-sensitive A2780 and Cisplatin-resistant A2780/CP gynecological cancer cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.